ANI Pharmaceuticals, Inc. announced the launch of Pindolol Tablets, 5mg and 10mg, which is used in the treatment of hypertension. The annual U.S. market for Pindolol Tablets is approximately $10 million, per IMS Health.
Arthur S. Przybyl, ANI’s President and CEO stated, “We are excited to launch the first product from our partnership with IDT Australia Ltd., which we entered in August 2015 and includes the exclusive rights to commercialize up to 18 previously marketed US generic drug products. We look forward to additional future launches through this partnership as we advance our collaboration.”
“This is a significant milestone for IDT and the ANI IDT partnership,” said Dr Paul MacLeman, IDT’s Managing Director. “Pindolol will be the first of IDT’s acquired generic drug products to be re-launched into the U.S.”
About Pindolol Tablet
Pindolol is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
About ANI
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com
Investor Relations
IR@anipharmaceuticals.com
